Search - tctmd.com

Displaying 21 - 40 of 153

Sort: Relevancy | Date

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

September 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

September 01, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

Semaglutide Has Similar Benefits in Women and Men With HFpEF

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

June 26, 2024

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

News Daily News

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

Michael O'Riordan

June 25, 2024

Don’t Worry About Muscle Loss With GLP-1 Inhibitors, Viewpoint Asserts

News Daily News

Don’t Worry About Muscle Loss With GLP-1 Inhibitors, Viewpoint Asserts

Yael L. Maxwell

June 10, 2024

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

May 17, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

April 04, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

February 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

February 01, 2024

January 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

January 01, 2024

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.